Sun Pharmaceutical Industries is finalizing a $12 billion binding offer for Organon & Co., which would mark the largest overseas acquisition by an Indian pharmaceutical company. Sun Pharma has completed three months of due diligence and is arranging financing with multiple global banks before submitting a firm bid in the coming weeks. The acquisition aligns with Sun Pharma's strategy to become a more innovation-driven, branded pharmaceutical player.

Sio Capital Management initiated a new $24.53 million position in Organon (OGN), purchasing 3.4 million shares at $6.03 per share. Despite the stock being down 61% over the past year, the investment signals potential turnaround opportunity as the pharmaceutical company focuses on stabilizing operations with flat 2026 guidance, supported by $1.9 billion in adjusted EBITDA despite declining revenues and profitability.

KDventures announced that Organon has discontinued development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was acquired as part of the Forendo portfolio company purchase in 2021. This marks the discontinuation of both drug candidates from the acquisition, following the earlier discontinuation of OG-6219 for endometriosis in July 2025. KDventures will write off its entire remaining book value of potential additional purchase considerations.

Organon has discontinued development of a preclinical drug candidate against PCOS that was part of the Forendo acquisition by KDventures in 2021. This marks the termination of both drug candidates from the acquisition, following the earlier discontinuation of OG-6219 for endometriosis in July 2025. KDventures will write off the entire remaining book value of the contingent consideration agreement related to the acquisition.

Sun Pharmaceutical Industries is reportedly evaluating a potential acquisition of Organon & Co, a U.S.-based women's healthcare company, in what could be India's largest cross-border pharma deal. Sun Pharma has submitted a non-binding all-cash bid with $10-14 billion in acquisition financing arranged. The deal, valued at approximately $10 billion including debt, would significantly strengthen Sun Pharma's presence in the U.S. market and women's health sector, though negotiations remain preliminary with no certainty of completion.

The inaugural National Women's Health Summit will take place in Toronto on March 24-25, 2026, bringing together health researchers, clinicians, and advocates to discuss critical women's health issues and potential innovations.

A national women's health summit will be held in Toronto on March 24-25, 2026, bringing together researchers, clinicians, and health advocates to discuss critical women's health issues and drive meaningful change.

The global contraceptive devices market is projected to grow from $20 billion in 2024 to $33 billion by 2032, driven by increased awareness, technological innovations, and changing demographic trends.

A new McKinsey Health Institute report reveals that Canadian women spend 24% more time in poor health than men, potentially costing the economy $37 billion annually by 2040. Women's Health Collective Canada advocates for increased investment in women's health research and care.

A new analysis reveals that investing in women's health could generate $37 billion in annual GDP by 2040, addressing significant health disparities where Canadian women spend 24% more time in poor health compared to men.

MoonLake Immunotherapeutics faced a securities class action lawsuit after reporting disappointing Phase 3 trial results for its sole drug candidate sonelokimab, causing a 90% stock price drop and investor losses.

Women's Health Collective Canada launched Vital Talks, a national online seminar series focusing on women's health, starting with a menopause care event supported by multiple healthcare and research partners.